
Available online on 15.08.2021 at <http://jddtonline.info>

## Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

Copyright © 2021 The Author(s). This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited



Open  Access Full Text Article



Research Article

### *In-silico* ADMET Pharmacoinformatics of Geraniol (3,7-dimethylocta-trans-2,6-dien-1-ol) - acyclic monoterpene alcohol drug from Leaf Essential Oil of *Cymbopogon martinii* from Sirumalai Hills (Eastern Ghats), INDIA

C. Kandeepan<sup>1</sup>, R.V. Kalaimathi<sup>1</sup>, A. Jeevalatha<sup>2</sup>, A. N. Basha<sup>2</sup>, S. Ramya<sup>3</sup>, R. Jayakumararaj<sup>3\*</sup><sup>1</sup> PG & Research Department of Zoology, Arulmigu Palaniandavar College of Arts & Culture, Palani – 624601, TamilNadu, India<sup>2</sup> Department of Zoology, GTN College, Dindigul, TamilNadu, India<sup>3</sup> Department of Botany, Government Arts College, Melur – 625106, Madurai, TamilNadu, India

#### Article Info:



#### Article History:

Received 12 June 2021  
 Reviewed 27 July 2021  
 Accepted 03 August 2021  
 Published 15 August 2021

#### Cite this article as:

Kandeepan C, Kalaimathi RV, Jeevalatha A, Basha AN, Ramya S, Jayakumararaj R, *In-silico* ADMET Pharmacoinformatics of Geraniol (3,7-dimethyl octa-trans-2,6-dien-1-ol) - acyclic monoterpene alcohol drug from Leaf Essential Oil of *Cymbopogon martinii* from Sirumalai Hills (Eastern Ghats), INDIA, Journal of Drug Delivery and Therapeutics. 2021; 11(4-S):109-118

DOI: <http://dx.doi.org/10.22270/jddt.v11i4-S.4965>

#### \*Address for Correspondence:

R. Jayakumararaj, Department of Botany,  
 Government Arts College, Melur – 625106,  
 Madurai, TamilNadu, India

#### Abstract

*Cymbopogon martinii* is a grass from genus *Cymbopogon* (lemongrasses) native to India, but widely cultivated in other places for its aromatic essential oil. *C. martinii* known as Palmarosa smells sweet with rose-like odor. Geraniol, a terpene alcohol present in *Cymbopogon martinii* essential oil (CMEO) is much valued for its typical aroma and medicinal uses. In addition to the pleasant odor, Geraniol is known for fungicidal, nematocidal, acaricidal, insecticidal, repellent properties hence, used as Natural Pest Control Agent (NPCA) exhibiting low toxicity. Furthermore, geraniol has been suggested to exemplify a new class of chemoprevention agents in the treatment of cancer. Biological activities such as antimicrobial, anti-oxidant, anti-inflammatory and vascular effects have been investigated. In the present study, GCMS based *in-silico* ADMET pharmacoinformatics aspects (Physicochemical, Lipophilicity, Medicinal Chemistry, Druglikeness, Absorption, Water Solubility, Distribution, Metabolism, Pharmacokinetics, Excretion, Environmental Toxicity, Tox21 Pathway and Toxicophore Rules) with PASS prediction of geraniol from CMEO has been bioprospected from human health perspective point of view.

**Keywords:** GCMS; ADMET; Pharmacoinformatics; Geraniol; Essential Oil; *Cymbopogon martinii*; Palmarosa; CMEO; PBNPs; Sirumalai Hills; Eastern Ghats

## INTRODUCTION

Geraniol (3,7-dimethylocta-trans-2,6-dien-1-ol) is acyclic monoterpene alcohol with chemical formula C<sub>10</sub>H<sub>18</sub>O. Referred to as "**Geraniol**" is a mixture of two cis-trans isomers namely geraniol (trans) and nerol (cis). Geraniol was first isolated from *Cymbopogon martinii* essential oil while nerol was obtained from neroli<sup>1,2</sup>. It is a common aromatic constituent present in essential oils several medicinal plants, however, with varying concentration in leaf/ floral tissues. Maximum EO content has been reported from *Monarda fistulosa*<sup>3</sup> (> 95.00%), followed by ninde oil<sup>4</sup> (66.00%), rose oil<sup>5</sup> (44.40%), palmarosa oil<sup>6</sup> (53.50%) and citronella oil<sup>7</sup> (24.80%).

Geraniol<sup>8</sup> is clear pale-yellow oil, insoluble in water, soluble in organic solvents. It is obtained from flowers of many species. It is also present in vegetative tissues of several species of herbs; most often geraniol and nerol are present together as the oxidation products of geraniol<sup>9</sup>. Geraniol has a typical rose-like odor; taste of Geraniol at a concentration

of 10 ppm is sweet<sup>10</sup> therefore, commonly used as a fragrance material world over. It has been reported that geraniol is the main component of deodorants (76%); domestic/ household products (41%); cosmetic formulations (33%) available in market world over. Geraniol as a plant based natural product (PBNPs) is directly used as natural ingredient in aforesaid products, to meet and feed the market demand its production exceeds 1000 mt per annum<sup>8</sup>.

Geraniol is well documented to exhibit biochemical and pharmacological properties. It has been shown that geraniol is an effective plant-based insect repellent. CMEO is of demand in the market as natural pest control agents due to its insecticidal, repellent and/or antifeedant properties<sup>11</sup>. Further, its low mammalian toxicity and biodegradability favor its development as a lead drug in many pharmaceutical products. Using an impregnated fabric disc bioassay Jeon et al. demonstrated the acaricidal activities of geraniol against storage food mite and compared the activity of geraniol to benzyl benzoate (acaricide) to show that geraniol was more effective than benzyl benzoate<sup>12</sup>.

Khallaayoune et al.<sup>13</sup> demonstrated that among four monoterpenes ( $\alpha$ -pinene, geraniol, limonene and p-cymene), geraniol, in a 5% dilution displayed the strongest acaricidal activity by direct contact with the mites<sup>14</sup>. In a study lemongrass oil extract added to 25% geraniol oil exhibited longest protection time against mosquitoes<sup>15</sup>. Müller et al.<sup>16</sup> determined the degree of personal protection provided by commercial citronella, linalool and geraniol candles or diffusers. Indoors, the repellency rate of geraniol candles was 50%, while the diffusers provided a repellency rate of 97%. Geraniol exerts in vitro and in vivo antitumor activity against murine leukemia, hepatoma and melanoma cells.<sup>17,18</sup>

*In-vitro* study demonstrated antibiofilm activity of carvacrol, geraniol, and thymol against *Candida*<sup>19</sup>. Acne - Palmarosa essential oil showed antibacterial activity against the bacteria that can cause skin acne with geraniol as the most likely active constituent. More research is warranted<sup>20</sup>. Anti-Allergy - Geraniol and beta-citronellol isolated from *P. graveolens* was effective against house dust mites<sup>21</sup>. Anti-

Parasite - Palmarosa and its geraniol constituent both showed potent anthelmintic activity against *Caenorhabditis elegans*<sup>22</sup>. Preservative - Essential oils of cilantro, coriander, cinnamon, oregano, rosemary, sage, clove, thyme, lemongrass, turmeric, mint, basil, and constituents of linalool, cinnamaldehyde, carvacrol, thymol, terpinene, cymene, alpha/beta pinene, bornyl acetate, camphor, 1,8-cineole, alpha terpineol, geraniol, perrilaldehyde, and eugenol have demonstrated food preserving potential.<sup>23</sup> Anti-Cancer - Citronellol, citronellyl formate, geraniol and citronellyl acetate from geranium oil exhibited marginal antitumor activities.<sup>24</sup> Repellent - Constituents of geranium oil demonstrated safe repelling action against the mosquito associated with the West Nile virus.<sup>25</sup> Antioxidant - Coriander seed essential oil and its major components of geraniol (24%), d-linanol (16%), borneol (7%),  $\alpha$ -pinene (9%) and  $\beta$ -pinene showed antioxidant activities in vitro.<sup>26</sup>

**The Plant Source:** *Cymbopogon martini* (Roxb.) Will. Watson<sup>27</sup>

### Systematic Position

**Class:** Equisetopsida C. Agardh  
**Subclass:** Magnoliidae Novák Ex Takht.  
**Superorder:** Liliales Takht.  
**Order:** Poales Small  
**Family:** Poaceae Barnhart  
**Genus:** *Cymbopogon* Spreng.  
**Species:** *C. martini* (Roxb.) Will. Watson.



**Common Name:** Palmarosa grass

**Vernacular Name:** Hindi - Rusa Ghas; Tamil - Kavathampullu; Marathi - Rohish

**Citation:** *Cymbopogon martini* (Roxb.) Will. Watson in Atkins., Bot. Himalayan Distr. N. W. Prov. 392. 1882; *Andropogon martini* Roxb., Fl. Ind. (Carey and Wallich ed.) 1: 280-281. 1820. Type: "A native of the high lands of Ballaghata, General Martin collected the seeds while there with the army, during the last war with Tippoo Sultan, and has reared abundance of it at Lucknow." *Andropogon schoenanthus* L. var. *martini* (Roxb.) Hook. f., Fl. Brit. India (J.D. Hooker). 7(21): 204. 1896; *Cymbopogon martini* (Roxb.) Will. Watson var. *sofia* B.K. Gupta, Proc. Indian Acad. Sci., B 71: 97. 1970. *Andropogon pachnodes* Trin., Mém. Acad. Imp. Sci. St. Pétersbourg, Sér. 6, Sci. Math. 2(3): 284. 1832. Type: Nepal; Wallich s.n.; *Cymbopogon pachnodes* (Trin.) Will. Watson in Atkins., Bot. Himalayan Distr. N.W. Prov. 392. 1882; *Cymbopogon motia* B.K. Gupta, Proc. Indian Acad. Sci., B 71: 92. 1970. Type: India; B.K. Gupta 25 (DD); *Cymbopogon martinianus* Schult., Mant. 2 (Schultes) 459. 1824, nom. superfl. & illegit. for *Andropogon martini* Roxb.

**Distribution:** Native to India - Andhra Pradesh, Assam, Bihar, Chhattisgarh, Goa, Gujarat, Himachal Pradesh, Karnataka, Kerala, Maharashtra, Odisha, Punjab, Rajasthan, Telangana, Tamil Nadu; Asia: China, Sri Lanka, Myanmar, Nepal, Bhutan, Bangladesh, Pakistan<sup>27</sup>.

**Habit:** *Cymbopogon martini* is Perennial. The grass is cultivated elsewhere in the tropics for its oils on commercial scale to meet the market demand of its essential oil. '**Motia**'

yields Palmarosa Essential Oil and '**Sofia**' yields Ginger-Grass Oil<sup>27</sup>.

**Botanical Description:** Perennial from a short woody rootstock. Culms tufted, up to 3 m tall, lower nodes often swollen, mealy. Leaf sheaths glabrous; leaf blades lanceolate, usually glaucous below, dark green above, up to 50 × 2-3 cm, glabrous, base cordate, often amplexicaul, apex filiform; ligule 2-4 mm. Spathate panicle narrow, dense, erect, 20-30 cm; spatheoles green becoming reddish, 2-4 cm; racemes 1.5-2 cm; rachis internodes and pedicels ciliate on margins, back sometimes pubescent; pedicel of homogamous pair swollen, barrel-shaped, shiny, fused to internode at base. Sessile spikelet oblong, 3.5-4.5 mm; lower glume flat, deeply grooved below middle (appearing as a line or keel on inside), keels winged above middle, vein-less or 2-veined between keels; upper lemma 2-lobed; awn 1.4-1.8 cm. Pedicelled spikelet 3.5-4 mm. Fl. and fr. Jul-Oct.

**Ethnobotanical Narration and Medicinal Uses:** *Cymbopogon martinii* Leaf decoction (CMLD) 50-60 ml is used to treat intestinal worms/ diarrhea and other gastro intestinal disorders (GID); paste of leaf and stem is applied over scabies affected area to restore discoloration of skin; PEO mixed with hot water is used for steam inhalation during asthma and common cold; leaf is boiled in cow milk (40-50 ml) and consumed orally to improve lactation in feeding mothers; CMLD 50-60 ml is used as blood purifier; CMLD improves the strength of cardiac muscles; *Cymbopogon martinii* Leaf Paste (CMLP) is applied over joints with pain and inflammation as part of treatment; cold infusion of leaf (50-60 ml) is given to treat fever and

anorexia. *C. martinii* is an Ayurvedic plant used in the treatment of joint pain, respiratory diseases, anorexia, intestinal worms, skin diseases and diarrhea.<sup>28-30</sup>

## MATERIALS AND METHODS

Collection, Preparation and Extraction of Oil from the leaf sample: The leaf samples were collected from wild in Sirumalai Region 10.1942° N, 77.9967° E; Elevation - 1,600 m (5,200 ft) (Part of Eastern Ghats, Dindigul District, TamilNadu, INDIA) during Feb 2021. The leaf sample were preserved, taken to laboratory, identified by using flora<sup>31,32</sup> shade dried and processed as per the protocol for preparation of sample according to the methods previously described by Soorya et al.<sup>30</sup> however, with modifications in the temperature and duration of processing of the sample. As much as 100 g leaf was weighed and dried in an oven at 60°C. Dried sample was ground to powder using Thomas Willey milling machine and sieved on a mesh screen (3×3 mm<sup>2</sup>). Sample was stored at 4°C in air-tight container with screw caps until further use. Sample was prepared according to the methods previously described by Soorya et al.<sup>30</sup> 25 g of sample was suspended in 250 mL of distilled water in stoppered flasks and allowed to stand for 24 h, filtered with Whatman No 24 filter paper, concentrated in a rotary evaporator for 12 h at 50°C and dried in vacuum desiccator. Yield was calculated; extract was suspended in ethyl acetate and subjected to GC-MS analysis.

### GC-MS Analysis

*Cymbopogon martini* Essential Oil (CMEO) was extracted, from the leaf samples collected from the Sirumalai Hills, Kodai Road Region, Dindigul District, Tamil Nadu, India. Phyto-components were identified using GC-MS detection system as described previously, however with modification, whereby portion of the extract was analysed directly by headspace sampling. GC-MS analysis was accomplished using an Agilent 7890A GC system set up with 5975C VL MSD (Agilent Technologies, CA, USA). Capillary column used was DB-5MS (30×0.25 mm, film thickness of 0.25 µm; J&W Scientific, CA, USA). Temperature program was set as follows: initial temperature 50°C held for 1 min, 5°C per min to 100°C, 9°C per min to 200°C held for 7.89 min, and the total run time was 30 min. The flow rate of helium as a carrier gas was 0.811851 mL/ min. MS system was performed in electron ionization (EI) mode with Selected Ion Monitoring (SIM). The ion source temperature and quadrupole temperature were set at 230°C and 150°C, respectively. Identification of phyto-components was performed by comparison of their retention times and mass with those of authentic standards spectra using computer searches in NIST 08.L and Wiley 7n.l libraries<sup>30</sup>.

### ADMET Prediction

Selected phytochemicals were subjected to ADMET prediction (SwissADME) and toxicity prediction using TOPKAT (Accelrys, Inc., USA). QikProp develops and employs QSAR/QSPR models using partial least squares, principal component analysis and multiple linear regression to predict physico-chemically significant descriptors<sup>33-35</sup>.

## RESULTS AND DISCUSSION

The bioactivity of plant secondary metabolites including essential oils (EOs) is known for their medicinal use, flavour and fragrance since ancient times. Furthermore, it has been well established that these secondary class of compounds significant influence the physiological process in the human body (increased and/or decreased).<sup>36-40</sup> Therefore, a clear understanding to their physiological, biochemical and

metabolic role of these compounds in human and animal system is warranted<sup>37,38</sup>. Accordingly, GCMS analysis has emerged as a powerful tool to analyse the composition of phytochemicals. GCMS analysis of phytochemicals in *Cymbopogon martinii* ethanolic leaf extract is given in Table 1.

**Physicochemical properties of Geraniol:** Molecular Weight (MW) (154.140); Volume (185.034); Density (0.833); Nhd (1); Nhd (1); nRot (4); nRing (0); MaxRing (0); NHet (1); FChar (0); NRig (2); Flexibility (2.000); Stereo Centers (0); TPSA (20.230); LogS (-2.718); LogP (3.606); LogD (2.719). **Lipophilicity properties:** Log  $P_{o/w}$  (iLOGP) (2.75); Log  $P_{o/w}$  (XLOGP3) (3.56); Log  $P_{o/w}$  (WLOGP) (2.67); Log  $P_{o/w}$  (MLOGP) (2.59); Log  $P_{o/w}$  (SILICOS-IT) (2.35); Consensus Log  $P_{o/w}$  (2.78); Medicinal Chemistry QED (0.617); SAScore (2.681); Fsp<sup>3</sup> (0.600); MCE-18 (0.000); NPscore (2.905); Lipinski Rule (Accepted); Pfizer Rule (Rejected); GSK Rule (Accepted); Golden Triangle (Rejected); PAINS (0 alert(s)); ALARM NMR Rule (0 alert(s)); BMS Rule (0 alert(s)); Chelator Rule (0 alert(s)); Brenk (1 alert: isolated alkene); Leadlikeness (No; 2 violations: MW<250, XLOGP3>3.5); Synthetic accessibility (2.58). **Druglikeness properties:** Lipinski (Yes; 0 violation); Ghose (No; 1 violation: MW<160); Veber (Yes); Egan (Yes); Muegge (No; 2 violations: MW<200, Heteroatoms<2); Bioavailability Score (0.55) (Table 2a).

**ADMET properties of Geraniol - Absorption:** The calculated value (in parenthesis) for Caco-2 Permeability (-4.299); MDCK Permeability (1.4e-05); Pgp-inhibitor (---); Pgp-substrate (---); HIA (---); F<sub>20%</sub> (+++); F<sub>30%</sub> (+++). **Water Solubility:** Log S (ESOL) (-2.78); Solubility (2.59e-01 mg/ml ; 1.68e-03 mol/l); Class (Soluble); Log S (Ali) (-3.67); Solubility (3.30e-02 mg/ml ; 2.14e-04 mol/l); Class (Soluble); Log S (SILICOS-IT) (-1.84); Solubility (2.20e+00 mg/ml ; 1.43e-02 mol/l); Class (Soluble). **Distribution properties:** PPB (88.865%); VD (3.402); BBB Penetration (+++); Fu (9.836%), **Metabolism properties:** CYP1A2 inhibitor (+); CYP1A2 substrate (-); CYP2C19 inhibitor (---); CYP2C19 substrate (-); CYP2C9 inhibitor (---); CYP2C9 substrate (++); CYP2D6 inhibitor (---); CYP2D6 substrate (-); CYP3A4 inhibitor (---); CYP3A4 substrate (-). In a study, CYP2B6 showed high activity in geraniol metabolism before CYP1A1 and CYP3A5. CYP1B1 and CYP2E1 showed low activity. Nevertheless, CYP1A1 and CYP3A5 are responsible for the majority of geraniol metabolism in the skin because they dominate in it<sup>40</sup>. Furthermore, CYP2B6 a dominant isoform of CYP involved in the metabolism of xenobiotics in the liver<sup>41-43</sup>. However, no pharmacokinetic and bioavailability data on geraniol are currently available<sup>42</sup>. Systematic elucidation of the mechanism of geraniol via network pharmacology, drug design, development and therapy indicated that geraniol has superb druggability with 38 putative identified target genes. GO, KEGG, and network analyses revealed that the targets were associated with cancer, inflammatory immunoreactions related physiological processes<sup>44</sup>.

Poor pharmacokinetics and toxicity are the most important causes of costly delays, further, they impede drug discovery and development<sup>44</sup>. **Pharmacokinetics properties:** GI absorption (High); BBB permeant (Yes); P-gp substrate (No). **Excretion properties:** CL (12.604); T<sub>1/2</sub> (0.737) (Table 2b). Comparative Toxicogenomics Database (CTD, <http://ctdbase.org/>), is a robust, publicly available database for toxicogenomic information. **Toxicity properties:** hERG Blockers (---); H-HT (+++); DILI (---); AMES Toxicity (---); Rat Oral Acute Toxicity (---); FDAMDD (---); Skin Sensitization (+++); Carcinogenicity (+); Eye Corrosion (+); Eye Irritation

(+++); Respiratory Toxicity (---). **Environmental Toxicity properties:** Bioconcentration Factors (0.939); IGC<sub>50</sub> (1.797); LC<sub>50</sub>FM (3.762); LC<sub>50</sub>DM (5.066). **Tox21 Pathway properties:** NR-AR (---); NR-AR-LBD (---); NR-AhR (---); NR-Aromatase (---); NR-ER (---); NR-ER-LBD (---); NR-PPAR-gamma (---); SR-ARE (---); SR-ATAD5 (---); SR-HSE (+); SR-MMP (---); SR-p53 (---). **Toxicophore Rules:** Acute Toxicity Rule (0 alert(s)); Genotoxic Carcinogenicity Rule (1 alert(s)); Non-Genotoxic Carcinogenicity Rule (0 alert(s)); Skin Sensitization Rule (1 alert(s)); Aquatic Toxicity Rule (0 alert(s)); Non-Biodegradable Rule (0 alert(s)); Sure-ChEMBL Rule (0 alert(s)); FAF-Drugs4 Rule (0 alert(s)) (Table 2c). Pharmacokinetic properties of geraniol meet the requirements, indicating that geraniol is an ideal candidate for drug development<sup>44</sup>.

The molecular properties of geraniol including bioavailability and membrane permeability have been linked with many fundamental molecular descriptors like logP (partition coefficient), molecular weight (MW), or number of hydrogen bond acceptors and donors in a molecule. The "rule of five" has been formulated by using these molecular properties<sup>45</sup>. It shows that the majority molecules having fine membrane permeability have molecular weight less than or equal to 500, calculated octanol-water partition coefficient, log P ≤ 5, hydrogen bond donors less than or equal to 5, and acceptors less than or equal to 10<sup>46</sup>. Hence, Lipinski's Rule of Five has been used to predict and test the biological availability of properties like absorption, distribution, metabolism, and elimination (ADME) of the main compounds. Geraniol including citronellol, alpha-terpineol, o-cymene, d-limonene, eucalyptol, alpha-pinene, and 3-carene obeyed the Lipinski's rule of five, as well as the compound possess properties of drug likeliness<sup>47</sup>.

As one of the best filters in the virtual screening of bioactive molecules, in order to be an effective drug in early preclinical development, the forecasting of ADME (absorption, distribution, metabolism and excretion) profiles of the selected compounds, including their pharmacokinetic and drug-like properties, have been investigated using Swiss ADME<sup>48</sup> (<http://www.swissadme.ch/>). The selected phytocompound geraniol correctly meet the Lipinski Rule of five, and also share topological polar surface area TPSA values less than 30 Å<sup>2</sup>, suggesting good brain penetration and good lipophilicity behaviour, which is expressed by the consensus Log Po/w in the range 2.25–4.75. Their bioavailability score of 0.55 indicates their more drug-like properties<sup>49</sup>. Noticeably, there is no P-glycoprotein (P-gp) substrate justifying their good intestinal absorption and bioavailability; the compounds exhibited high gastrointestinal absorption (GI) (except α-selinene), and only isocembrol and α-selinene were predicted to not cross the blood–brain barrier (BBB). However, the others easily pass the blood–brain barrier (BBB) permeant, and can bind to specific receptors. The study's components interacted at most with two isoenzymes of the Cytochrome P (CYP) family, confirming their better effectiveness with insignificant toxicity (Table 2a,b,c).

Target identification and mechanism of action in chemical biology significantly influence drug discovery.<sup>50</sup> PASS (Prediction of Activity Spectra for Substances) is a tool for evaluating the general biological potential of an organic drug-like molecule. PASS provides simultaneous predictions of many types of biological activity based on the structure of organic compounds. Thus, PASS can be used to estimate the biological activity profiles for virtual molecules, prior to their chemical synthesis and biological testing. Pa (probability "to be active") estimates the chance that the studied compound

is belonging to the sub-class of active compounds (resembles the structures of molecules, which are the most typical in a sub-set of "actives" in PASS training set). Pi (probability "to be inactive") estimates the chance that the studied compound is belonging to the sub-class of inactive compounds. PASS prediction of activity spectra of geraniol is given in Table 3a,b.

## CONCLUSIONS

Medicinal plants have proven record as a source of biomolecules with therapeutic potential represent a pool for novel drug leads. In the past, pharmaceutical industry focused on libraries of synthetic compounds as drug discovery source. They are comparably easy to produce and resupply, and demonstrate good compatibility with established high throughput screening (HTS) platforms. However, a declining trend in the number of new drugs reaching the market, raising renewed scientific interest in drug discovery from natural sources, despite of its known challenges. Geraniol the main component of CMEO is a widely used as a fragrance compound in cosmetic and household products, but due to its wide array of biological activities - antimicrobial, antioxidant, anti-inflammatory, anticancer with significantly low-toxicity *vis-a-vis* proven high efficacy, it can potentially be a part of new class of therapeutic agents against several human diseases. To sum-up, geraniol is an active ingredient/ promising candidate for the development of effective multi-targeted anticancer medicament of GRAS standard. Nevertheless, its potential interactions with other biologically active substances warrant in-depth research in particular *in vitro* and animal models through clinical trials to lead the pharma-market.

## REFERENCES

1. Bedoukian PZ. Geraniol and nerol. *Perfumery and Flavoring Synthetics*. 1986.
2. Clark GS. Geraniol. *Perfumer & flavorist*. 1998; 23(3):19-25.
3. Simon DZ, Beliveau J, Aube C. Extraction by hydrodiffusion of the essential oil of *Monarda fistulosa* grown in the province of Quebec: Assay of geraniol in the hydro-diffused oil. *International Journal of Crude Drug Research*. 1986; 24(3):120-2. <https://doi.org/10.3109/13880208609060888>
4. Baser KH, Kürkcüoğlu M, Demirci B. Ninde oil (*Aeollanthus myrianthus* Taylor) revisited: analysis of historical oil. *Journal of essential oil research*. 2005; 17(2):137-8. <https://doi.org/10.1080/10412905.2005.9698856>
5. Baydar H, Baydar NG. The effects of harvest date, fermentation duration and Tween 20 treatment on essential oil content and composition of industrial oil rose (*Rosa damascena* Mill.). *Industrial crops and products*. 2005; 21(2):251-5. <https://doi.org/10.1016/j.indcrop.2004.04.004>
6. Dubey VS, Luthra R. Biotransformation of geranyl acetate to geraniol during palmarosa (*Cymbopogon martinii*, Roxb. wats. var. motia) inflorescence development. *Phytochemistry*. 2001; 57(5):675-80. [https://doi.org/10.1016/S0031-9422\(01\)00122-4](https://doi.org/10.1016/S0031-9422(01)00122-4)
7. Rajeswara Rao BR, Bhattacharya AK, Mallavarapu GR, Ramesh S. Yellowing and crinkling disease and its impact on the yield and composition of the essential oil of citronella (*Cymbopogon winterianus* Jowitt.). *Flavour and fragrance journal*. 2004; 19(4):344-50. <https://doi.org/10.1002/ffj.1313>
8. Chen W, Viljoen AM. Geraniol-a review of a commercially important fragrance material. *South African Journal of Botany*. 2010; 76(4):643-51. <https://doi.org/10.1016/j.sajb.2010.05.008>
9. Regev S, Cone WW. Analyses of pharate female two spotted spider mites for nerolidol and geraniol: evaluation for sex attraction of males. *Environmental Entomology*. 1976; 5(1):133-8. <https://doi.org/10.1093/ee/5.1.133>
10. Burdock Geranio Fenaroli's Handbook of Flavor Ingredients (6th ed), CRC Press (2010), pp. 733-734

11. Barnard DR, Xue RD. Laboratory evaluation of mosquito repellents against *Aedes albopictus*, *Culex nigripalpus*, and *Ochlerotatus triseriatus* (Diptera: Culicidae). *Journal of medical entomology*. 2004; 41(4):726-30. <https://doi.org/10.1603/0022-2585-41.4.726>
12. Jeon JH, Lee CH, Lee HS. Food protective effect of geraniol and its congeners against stored food mites. *Journal of food protection*. 2009; 72(7):1468-71. <https://doi.org/10.4315/0362-028X-72.7.1468>
13. Khallaayoune K, Biron JM, Chaoui A, Duvallet G. Efficacy of 1% geraniol (Fulltec®) as a tick repellent. *Parasite*. 2009; 16(3):223-6. <https://doi.org/10.1051/parasite/2009163223>
14. Traina O, Cafarchia C, Capelli G, Iacobellis NS, Otranto D. In vitro acaricidal activity of four monoterpenes and solvents against *Otodectes cynotis* (Acari: Psoroptidae). *Experimental & applied acarology*. 2005; 37(1-2):141.
15. Qualls WA, Xue RD. Field evaluation of three botanical repellents against *Psorophora ferox*, *Aedes atlanticus*, and *Aedes mitchellae*. *Journal of the American Mosquito Control Association*. 2009; 25(3):379-81. <https://doi.org/10.2987/09-5850.1>
16. Müller GC, Junnila A, Butler J, Kravchenko VD, Revay EE, Weiss RW, Schlein Y. Efficacy of the botanical repellents geraniol, linalool, and citronella against mosquitoes. *Journal of Vector Ecology*. 2009; 34(1):2-8. <https://doi.org/10.1111/j.1948-7134.2009.00002.x>
17. Burke YD, Stark MJ, Roach SL, Sen SE, Crowell PL. Inhibition of pancreatic cancer growth by the dietary isoprenoids farnesol and geraniol. *Lipids*. 1997; 32(2):151-6. <https://doi.org/10.1007/s11745-997-0019-y>
18. ChO MI, So I, Chun JN, Jeon JH. The antitumor effects of geraniol: Modulation of cancer hallmark pathways. *International journal of oncology*. 2016; 48(5):1772-82. <https://doi.org/10.3892/ijo.2016.3427>
19. Dalleau S, Cateau E, Berges T, Berjeaud JM, Imbert C. In vitro activity of terpenes against *Candida* biofilms. *International journal of antimicrobial agents*. 2008; 31(6):572-6. <https://doi.org/10.1016/j.ijantimicag.2008.01.028>
20. Andrade BM, Barbosa LN, Alves FB, Albano M, Fernandes RK, Gorgulho CM, Júnior AF, Brüggemann H. *Cymbopogon martinii* essential oil: chemical characterization, effects on *Propionibacterium* acnes and immune response in lymphocytes. *Planta Medica*. 2016; 82(S 01):P185.
21. Jeon JH, Kim HW, Kim MG, Lee HS. Mite-control activities of active constituents isolated from *Pelargonium graveolens* against house dust mites. *Journal of microbiology and biotechnology*. 2008; 18(10):1666-71.
22. Kumaran AM, D'Souza P, Agarwal A, Bokkolla RM, Balasubramaniam M. Geraniol, the putative anthelmintic principle of *Cymbopogon martinii*. *Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives*. 2003; 17(8):957-. <https://doi.org/10.1002/ptr.1267>
23. Burt S. Essential oils: their antibacterial properties and potential applications in foods—a review. *International journal of food microbiology*. 2004; 94(3):223-53. <https://doi.org/10.1016/j.ijfoodmicro.2004.03.022>
24. Fang HJ, Su XL, Liu HY, Chen YH, Ni JH. Studies on the chemical components and anti-tumour action of the volatile oils from *Pelargonium graveoleus*. *Yao xue xue bao = Acta pharmaceutica Sinica*. 1989; 24(5):366-71.
25. Tabari MA, Youssefi MR, Esfandiari A, Benelli G. Toxicity of  $\beta$ -citronellol, geraniol and linalool from *Pelargonium roseum* essential oil against the West Nile and filariasis vector *Culex pipiens* (Diptera: Culicidae). *Research in veterinary science*. 2017; 114:36-40. <https://doi.org/10.1016/j.rvsc.2017.03.001>
26. González-Marrugo LB, Granados-Llamas EA, Granados-Conde C, Tejada-Tovar CN, Ortega-Toro R. Extraction and evaluation of the antioxidant properties of coriander (*Coriandrum sativum*) seed essential oil. *Contemporary Engineering Sciences*. 2018; 77:3841-8. <https://doi.org/10.12988/ces.2018.87356>
27. Kellogg E, Abbott JR, Bawa K, Gandhi K, Kailash BR, Ganeshiah KN, Shrestha UB, Raven P. Checklist of the grasses of India. *PhytoKeys*. 2020; 163:1. <https://doi.org/10.3897/phytokeys.163.38393>
28. Gebashe F, Moyo M, Aremu AO, Finnie JF, Van Staden J. Ethnobotanical survey and antibacterial screening of medicinal grasses in KwaZulu-Natal Province, South Africa. *South African Journal of Botany*. 2019; 122:467-74. <https://doi.org/10.1016/j.sajb.2018.07.027>
29. Avoseh O, Oyedeji O, Rungqu P, Nkeh-Chungag B, Oyedeji A. *Cymbopogon* species; ethnopharmacology, phytochemistry and the pharmacological importance. *Molecules*. 2015 May; 20(5):7438-53.
30. Soorya C, Balamurugan S, Basha AN, Kandeepan C, Ramya S, Jayakumararaj R. Profile of Bioactive Phyto-compounds in Essential Oil of *Cymbopogon martinii* from Palani Hills, Western Ghats, INDIA. *Journal of Drug Delivery and Therapeutics*. 2021; 11(4):60-5. <https://doi.org/10.22270/jddt.v11i4.4887>
31. Matthew KM. Flora of the Tamilnadu Carnatic. The Rapinat Herbarium, St. Joseph's College, Tiruchirappalli, India; 1981
32. Gamble JS, & Fischer CE. Flora of the Presidency of Madras. London, UK: West, Newman and Adlard; 1915. <https://doi.org/10.5962/bhl.title.21628> <https://doi.org/10.5962/bhl.title.21628>
33. Soorya C, Balamurugan S, Ramya S, Neethirajan K, Kandeepan C, & Jayakumararaj R. Physicochemical, ADMET and Druggable properties of Myricetin: A Key Flavonoid in *Syzygium cumini* that regulates metabolic inflammations. *Journal of Drug Delivery and Therapeutics*, 2021; 11(4):66-3. <https://doi.org/10.22270/jddt.v11i4.4890>
34. Gleeson M P. Generation of a set of simple, interpretable ADMET rules of thumb *J Med Chem*, 2008, 51(4): 817-34.
35. Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, Yin M, Zeng X, Wu C, Lu A, Chen X. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. *Nucleic Acids Research*. 2021 Apr 24.
36. Ramya S, & Jayakumararaj R. Antifeedant activity of selected ethno-botanicals used by tribals of Vattal Hills on *Helicoverpa armigera* (Hübner). *Journal of Pharmacy Research*. 2009; 2(8):1414-1418.
37. Ramya S, Neethirajan K & Jayakumararaj R. Profile of bioactive compounds in *Syzygium cumini*-a review. *J. Pharm. Res* 2012; 5(8):4548-4553.
38. Sundari A & Jayakumararaj R. Herbal remedies used to treat skin disorders in Arasankulam region of Thoothukudi District in Tamil Nadu, India. *Journal of Drug Delivery and Therapeutics*, 2020; 10(5):33-38. <https://doi.org/10.22270/jddt.v10i5.4277>
39. Sundari A & Jayakumararaj R. Medicinal plants used to cure cuts and wounds in Athur region of Thoothukudi district in Tamil Nadu, India. *Journal of Drug Delivery and Therapeutics*, 2020; 10(6-s):26-30.
40. Zehetner P, Höferl M, Buchbauer G. Essential oil components and cytochrome P450 enzymes: a review. *Flavour and Fragrance Journal*. 2019 Jul; 34(4):223-40.
41. Ekins S, Wrighton SA. The role of CYP2B6 in human xenobiotic metabolism. *Drug metabolism reviews*. 1999; 31(3):719-54. <https://doi.org/10.1081/DMR-100101942>
42. Pavan B, Dalpiaz A, Marani L, Beggato S, Ferraro L, Canistro D, Paolini M, Vivarelli F, Valerii MC, Comparone A, De Fazio L. Geraniol pharmacokinetics, bioavailability and its multiple effects on the liver antioxidant and xenobiotic-metabolizing enzymes. *Frontiers in pharmacology*. 2018; 9:18. <https://doi.org/10.3389/fphar.2018.00018>
43. Ertl P, Schuffenhauer A. Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions *J Cheminform*, 2009; 1(1): 8.
44. Zhang YF, Huang Y, Ni YH, Xu ZM. Systematic elucidation of the mechanism of geraniol via network pharmacology. *Drug design, development and therapy*. 2019; 13:1069. <https://doi.org/10.2147/DDDT.S189088>
45. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced drug delivery reviews*. 1997; 23(1-3):3-25.
46. Muegge I. Selection criteria for drug-like compounds. *Medicinal research reviews*. 2003; 23(3):302-21. <https://doi.org/10.1002/med.10041>
47. Panikar S, Shoba G, Arun M, Sahayarayan JJ, Nanthini AU, Chinnathambi A, Alharbi SA, Nasif O, Kim HJ. Essential oils as an effective alternative for the treatment of COVID-19: Molecular interaction analysis of protease (Mpro) with pharmacokinetics and toxicological properties. *Journal of Infection and Public*

Health. 2021; 14(5):601-10.


<https://doi.org/10.1016/j.jiph.2020.12.037>

48. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific reports. 2017; 7(1):1-3. <https://doi.org/10.1038/srep42717>

49. Leeson PD. Molecular inflation, attrition and the rule of five. Adv Drug Deliv Rev. 2016; 101:22-33.

<https://doi.org/10.1016/j.addr.2016.01.018>

50. Schenone M, Dančik V, Wagner BK, Clemons PA. Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol. 2013; 9(4):232-240 <https://doi.org/10.1038/nchembio.1199>



**Figure 1: Phytocompound physiochemical properties of Geraniol; a) 2D, b) 3D, c) Boiled Egg Model; d) Bioavailability Radar Map, e) Upper Limit; f) Lower Limit; g) Compound Properties; h) Cumulative map.**

**Table 1 GCMS analysis of *Cymbopogon martinii* leaf extract**

SNO	RT	COMPOUND	AREA
1.	13.2	$\alpha$ -Pinene	0.01
2.	18.5	$\beta$ -Pinene	0.01
3.	22.3	$\beta$ -Myrcene	0,24
4.	25.0	Limonene	0,17
5.	25.2	Isopentanol	0,02
6.	25.8	1,8-Cineole	0,12
7.	27.5	Cis-B-Ocimene	0,39
8.	28.8	Trans-B-Ocimene	1,63
9.	30.3	P-CYMENE	0,01
10.	31.2	Terpinolene	0,01
11.	35.1	6-Methyl-5-Hepten-2-One	0,03
12.	44.5	Menthone	0,06
13.	45.3	Citronellal	0,01
14.	46.5	Isomenthone	0,02
15.	49.3	Linalool	1,82
16.	50.0	1-Octanol	0,01
17.	50.2	Linalyl Acetate	0,01
18.	50.9	Menthyl Acetate	0,01
19.	52.8	$\beta$ -ELEMENE	0,05
20.	53.5	$\beta$ -Caryophyllene	1,07
21.	55.6	Menthol	0,63
22.	56.8	Trans-Pinocarveol	0,01
23.	57.0	Pulegone	0,01
24.	57.2	E- $\beta$ -Farnesene	0,01
25.	58.2	$\alpha$ -Humulene	0,07
26.	58.6	Neral	0,22
27.	59.2	$\alpha$ -Terpineol	0,02
28.	59.4	$\gamma$ -Selinene	0,01

29.	59.7	Geranyl Formate	0,09
30.	60.6	Germacrene D	0,02
31.	61.7	Geranial	0,62
32.	61.8	Piperitone	0,01
33.	63.0	Geranyl Acetate	13,45
34.	63.6	$\gamma$ -Cadinene	0,01
35.	65.2	Nerol	0,13
36.	68.2	<b>Geraniol</b>	<b>76,97</b>
37.	70.8	Geranyl Butyrate	0,11
38.	72.2	Geranic Ester	0,04
39.	75.6	Aliphatic Ester	0,03
40.	76.3	Isocaryophyllene Oxyde	0,02
41.	76.9	Caryophyllene Oxyde	0,12
42.	78.4	Nerolidol	0,07
43.	78.7	Caprylic Acid	0,01
44.	81.3	Geranyl Caproate	0,48
45.	81.7	Aliphatic Ester	0,07
46.	83.5	Aliphatic Alcohol	0,05
47.	87.6	Sesquiterpenol	0,01
48.	90.0	Farnesyl Acetate	0,10
49.	91.2	Geranyl Caprylate	0,10
50.	92.3	Geranic Acid	0,02
51.	94.1	Farnesol	0,71
52.	97.1	Precocene li Mw=220	0,03
53.			<b>100,00</b>

**Table 2a Physicochemical properties of Geraniol**

PROPERTY	VALUE
<b>Physicochemical</b>	
Molecular Weight (MW)	154.140
Volume	185.034
Density	0.833
Nha	1
Nhd	1
nRot	4
nRing	0
MaxRing	0
NHet	1
FChar	0
NRig	2
Flexibility	2.000
Stereo Centers	0
TPSA	20.230
LogS	-2.718
LogP	3.606
LogD	2.719
<b>Lipophilicity</b>	
Log $P_{o/w}$ (iLOGP)	2.75
Log $P_{o/w}$ (XLOGP3)	3.56
Log $P_{o/w}$ (WLOGP)	2.67
Log $P_{o/w}$ (MLOGP)	2.59
Log $P_{o/w}$ (SILICOS-IT)	2.35
Consensus Log $P_{o/w}$	2.78

<b>Medicinal Chemistry</b>	
QED	0.617
SAscore	2.681
Fsp <sup>3</sup>	0.600
MCE-18	0.000
NPscore	2.905
Lipinski Rule	Accepted
Pfizer Rule	Rejected
GSK Rule	Accepted
Golden Triangle	Rejected
PAINS	0 alert(s)
ALARM NMR Rule	0 alert(s)
BMS Rule	0 alert(s)
Chelator Rule	0 alert(s)
Brenk	1 alert: isolated alkene
Leadlikeness	No; 2 violations: MW<250, XLOGP3>3.5
Synthetic accessibility	2.58
<b>Druglikeness</b>	
Lipinski	Yes; 0 violation
Ghose	No; 1 violation: MW<160
Veber	Yes
Egan	Yes
Muegge	No; 2 violations: MW<200, Heteroatoms<2
Bioavailability Score	0.55

**Table 2b ADMET properties of Geraniol**

<b>Absorption</b>	
Caco-2 Permeability	-4.299
MDCK Permeability	1.4e-05
Pgp-inhibitor	---
Pgp-substrate	---
HIA	---
F <sub>20%</sub>	+++
F <sub>30%</sub>	+++
<b>Water Solubility</b>	
Log S (ESOL)	-2.78
Solubility	2.59e-01 mg/ml ; 1.68e-03 mol/l
Class	Soluble
Log S (Ali)	-3.67
Solubility	3.30e-02 mg/ml ; 2.14e-04 mol/l
Class	Soluble
Log S (SILICOS-IT)	-1.84
Solubility	2.20e+00 mg/ml ; 1.43e-02 mol/l
Class	Soluble
<b>Distribution</b>	
PPB	88.865%
VD	3.402
BBB Penetration	+++
Fu	9.836%
<b>Metabolism</b>	
CYP1A2 inhibitor	+
CYP1A2 substrate	--
CYP2C19 inhibitor	---
CYP2C19 substrate	-

CYP2C9 inhibitor	---
CYP2C9 substrate	++
CYP2D6 inhibitor	---
CYP2D6 substrate	--
CYP3A4 inhibitor	---
CYP3A4 substrate	--
<b>Pharmacokinetics</b>	
GI absorption	High
BBB permeant	Yes
P-gp substrate	No
<b>Excretion</b>	
CL	12.604
T <sub>1/2</sub>	0.737
<b>Toxicity</b>	
hERG Blockers	---
H-HT	+++
DILI	---
AMES Toxicity	---
Rat Oral Acute Toxicity	---
FDAMDD	---
Skin Sensitization	+++
Carcinogenicity	+
Eye Corrosion	+
Eye Irritation	+++
Respiratory Toxicity	---

Note: For classification endpoints, the prediction probability values are transformed into six symbols:

0-0.1(---); 0.1-0.3(--); 0.3-0.5(-); 0.5-0.7(+); 0.7-0.9(++); and 0.9-1.0(+++)

**Table 2c Toxicological properties of Geraniol**

<b>Environmental Toxicity</b>	
Bioconcentration Factors	0.939
IGC <sub>50</sub>	1.797
LC <sub>50</sub> FM	3.762
LC <sub>50</sub> DM	5.066
<b>Tox21 Pathway</b>	
NR-AR	---
NR-AR-LBD	---
NR-AhR	---
NR-Aromatase	---
NR-ER	---
NR-ER-LBD	---
NR-PPAR-gamma	---
SR-ARE	---
SR-ATAD5	---

SR-HSE	+
SR-MMP	---
SR-p53	---
<b>Toxicophore Rules</b>	
Acute Toxicity Rule	0 alert(s)
Genotoxic Carcinogenicity Rule	1 alert(s)
NonGenotoxic Carcinogenicity Rule	0 alert(s)
Skin Sensitization Rule	1 alert(s)
Aquatic Toxicity Rule	0 alert(s)
NonBiodegradable Rule	0 alert(s)
SureChEMBL Rule	0 alert(s)
FAF-Drugs4 Rule	0 alert(s)



**Table 3a PASS predicted possible functional effects**

<i>Pa</i>	<i>Pi</i>	<b>Predicted Functional Role/ Effect</b>
0.161	0.052	(N-acetylneuraminy)-galactosylglucosylceramide N-acetylgalactosaminyltransferase inhibitor
0.467	0.059	(R)-6-hydroxynicotine oxidase inhibitor
0.505	0.023	(R)-Pantolactone dehydrogenase (flavin) inhibitor
0.185	0.009	(R)-aminopropanol dehydrogenase inhibitor
0.109	0.076	(R)-limonene 6-monooxygenase inhibitor
0.205	0.043	(R,R)-butanediol dehydrogenase inhibitor
0.134	0.014	(S)-2-Methylmalate dehydratase inhibitor
0.179	0.031	(S)-2-hydroxy-acid oxidase inhibitor
0.261	0.033	(S)-3-amino-2-methylpropionate transaminase inhibitor
0.206	0.050	(S)-3-hydroxyacid ester dehydrogenase inhibitor
0.370	0.068	(S)-6-hydroxynicotine oxidase inhibitor
0.285	0.007	(S)-carnitine 3-dehydrogenase inhibitor
0.254	0.052	1,2-alpha-L-fucosidase inhibitor
0.051	0.033	1,3-Beta-glucan synthase inhibitor
0.373	0.013	1,4-Alpha-glucan branching enzyme inhibitor
0.673	0.012	1,4-Lactonase inhibitor
0.239	0.014	1,5-Anhydro-D-fructose reductase inhibitor
0.337	0.069	1-Acylglycerol-3-phosphate O-acyltransferase inhibitor
0.227	0.003	1-Alkyl-2-acetyl glycerol O-acyltransferase inhibitor
0.036	0.010	1-Alkyl-2-acetyl glycerophosphocholine esterase inhibitor
0.513	0.024	1-Alkyl glycerophosphocholine O-acetyltransferase inhibitor
0.274	0.009	1-Aminocyclopropane-1-carboxylate deaminase inhibitor
0.060	0.027	1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor
0.059	0.038	1-Phosphofructokinase inhibitor
0.110	0.029	1-Pyrroline-5-carboxylate dehydrogenase inhibitor
0.246	0.003	11-Cis-retinyl-palmitate hydrolase inhibitor
0.075	0.061	12-Lipoxygenase inhibitor
0.364	0.018	15-Hydroxyprostaglandin-D dehydrogenase (NADP+) inhibitor
0.096	0.026	15-Lipoxygenase inhibitor
0.257	0.021	2,2-Dialkylglycine decarboxylase (pyruvate) inhibitor
0.458	0.015	2,3-Dihydroxyindole 2,3-dioxygenase inhibitor
0.713	0.001	2,3-Oxidosqualene-lanosterol cyclase inhibitor
0.351	0.021	2,4-Diaminopentanoate dehydrogenase inhibitor

**Table 3b PASS predicted possible adverse and toxic effects**

<i>Pa</i>	<i>Pi</i>	Predicted possible Adverse/ Toxic Effect(s)
0.951	0.002	Skin irritation, moderate
0.925	0.005	Anemia
0.919	0.003	Skin irritative effect
0.895	0.004	Skin irritation, high
0.878	0.004	Hyperglycemic
0.875	0.012	Hepatotoxic
0.866	0.005	Non mutagenic, Salmonella
0.840	0.003	Eye irritation, weak
0.825	0.009	Edema
0.831	0.016	Ocular toxicity
0.832	0.020	Hematotoxic
0.814	0.006	Thrombocytopoiesis inhibitor
0.807	0.003	Lacrimal secretion stimulant
0.806	0.005	Eye irritation, high
0.800	0.022	Conjunctivitis
0.773	0.004	Acneiform eruption
0.792	0.026	Diarrhea
0.787	0.027	Toxic, gastrointestinal
0.761	0.029	Dermatitis
0.739	0.018	Embryotoxic
0.723	0.007	Irritation
0.742	0.031	Toxic, respiration
0.759	0.055	Shivering
0.717	0.014	Hypomagnesemia
0.703	0.003	Hypocalcaemic
0.711	0.020	Dyspnea
0.694	0.009	Visual acuity impairment
0.723	0.040	Toxic
0.710	0.035	Drowsiness
0.737	0.078	Twitching
0.700	0.042	Pure red cell aplasia
0.678	0.027	Inflammation
0.674	0.036	Hepatitis
0.656	0.028	Teratogen